Ticagrelor Powder CAS 274693-27-5

In recent years, with the development of social economy and the improvement of people's living standards, the incidence of thrombus diseases is rising year by year, and the increasingly serious aging population has promoted the further expansion of this market. Myocardial infarction is the most deadly disease, cerebral infarction is the most disabling disease, and the occurrence of these malignant diseases are directly related to thrombosis. As a result, today's antithrombotic drug market is developing very fast and has become one of the hot areas of global drug development.

Ticagrelor Powder is the first reversible ADP receptor antagonist with the chemical structure of cyclopentatriazophosphomidine that acts directly on P2Y12 receptors without metabolic activation. The study showed that Ticagrelor compared with clopidogrel significantly reduced primary endpoint events such as heart attack, stroke, or cardiovascular death in patients with no increase in severe bleeding complications. Studies have also shown that Ticagrelor and Clopidogrel work differently. Clopidogrel has an irreversible effect on platelets, which remain intact for a week, but after stopping ticagrelor treatment, this effect is quickly diminished or reversed, and platelets rise within two days. This difference is important for patients with excessive bleeding during surgery. Patients with rapid reversal are more suitable for coronary artery bypass surgery or have multiple vessel disease and may undergo bypass surgery. This is a challenge for patients with poor adherence, and missing medication can lead to a heart attack or stroke.